The Trump administration’s announcement of escalating tariffs on imported generic medicines could disrupt India’s vital pharmaceutical exports, prompting Indian firms to rethink onshore manufacturing strategies amid geopolitical shifts.
India’s place at the centre of the global generic drug trade is under fresh pressure after Donald Trump said the United States will begin taxing imported generic medicines at 100% from August 2028, rising to 200% a year later. The move, announced on Truth Social on July 21, is meant to push more production back onshore and could reshape supply chains that have long depended on Indian manufacturers, according to reporting by the South China Morning Post and other outlets.
The scale of the risk is significant. India Ratings and Research says the US takes about 35% of India’s pharmaceutical export revenue, while leading US-focused Indian drugmakers generated nearly $11 billion in sales in the financial year ended March 2026. Because generic medicines make up around 90% of prescriptions filled in the US, any disruption could have consequences not just for Indian firms but also for American patients and pharmacies that rely on low-cost supply.
Analysts quoted by the South China Morning Post said the tariff threat could force Indian companies to build or expand manufacturing in the US, raising costs and complicating operations. Vivek Mishra, deputy director of the Strategic Studies Programme at the Observer Research Foundation, said the policy signals a need for Indian drugmakers to establish a stronger US presence and could unsettle existing supply chains.
Other reports, including Business Standard, The Straits Times, NDTV, Investing.com, The Fiscal Times and The Spokesman-Review, said the same tariff schedule would start in August 2028 and climb to 200% in August 2029. Together, the accounts point to a longer-term effort by the Trump administration to reshape pharmaceutical manufacturing, but one that could test India’s export-led model and raise questions about how quickly the US can replace established foreign suppliers.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
